Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

Clinical Trials for Cancer Vaccines Initiated in Hungary

Hungary is accelerating the testing of innovative cancer vaccines amidst a decline in clinical studies in the region.
Barótfi Szabolcs, the clinical research director at MSD, noted a decrease in new clinical trials initiated annually in Hungary, indicating a loss of competitiveness in Europe compared to regions like Asia and North America.

Significantly, Poland and the Czech Republic now surpass Hungary in the number of clinical trials being conducted, which have seen an increase relative to other European nations.

Research indicates that institutional overload is a key issue, with increased burdens on staff leading to a decline in patient recruitment for clinical studies.

Additionally, recent data suggests that revisions in compensation structures for physicians have not effectively motivated participation in clinical trials.

Although there have been improvements in transparency regulations, the bureaucratic procedures in hospital administrations have become more cumbersome, resulting in delayed contract signings within multiple healthcare institutions.

Barótfi emphasized that participation in clinical research allows physicians to engage with the international scientific community and familiarize themselves with the mechanisms of treatments before they are marketed.

The costs associated with drug development have tripled over the past fifty years, with the average expense of bringing a new drug to market now estimated at $1.5 billion and a development timeline of 10 to 15 years.

For rare diseases, these costs can escalate to as high as $3 billion, with clinical phases consuming approximately half of these resources.

From ten thousand initial ideas, only a few hundred molecules advance to preclinical tests, and a mere fraction proceed to human trials, where still 30% may fail during the costly late clinical phases.

Artificial intelligence is emerging as a critical asset in this challenging landscape, being utilized to identify potential drugs early in the development process and to streamline patient recruitment for clinical trials.

This technology efficiently selects suitable patients from populations, reducing the need for physicians to sift through extensive patient data, thus facilitating better recruitment rates.

Currently, only 5% of eligible patients in oncology participate in clinical trials, potentially denying them additional treatment opportunities.

Barótfi suggested that decentralizing trials and extending recruitment options to local clinics could improve this percentage.

He also noted the potential of utilizing social media for patient recruitment, though current regulations in Hungary are conservative in this regard.

AI is also being applied in monitoring side effects, enabling real-time feedback through targeted search capabilities focused on specific drug products, significantly enhancing patient safety.

Furthermore, advancements in technology have presented opportunities for optimizing drug dosages by modeling interactions between medications in patients with multiple comorbidities, particularly in oncology.

The impact of tighter medical supervision on patient conditions could lead to improved prognoses, as Barótfi noted the potential for newly developed treatments to enhance long-term survival, particularly in the context of recent advancements in immunotherapy over the past 15 years.

Clinical trials for oncology drugs are initiated with patients in advanced stages (Stage 4) and then proceed to earlier stages.

Concerns about unknown side effects and fears of being assigned to placebo groups persist among patients, although Barótfi clarified that patients continue to receive their standard therapies along with the investigational drugs as per regulatory requirements.

Testing is underway in Hungary for mRNA-based technologies aimed at harnessing the immune system against cancer cells.

This personalized approach is being evaluated in trials involving advanced lung, breast, and bladder cancer patients.

The pandemic has underscored the capacity for rapid vaccine development through an unprecedented collaboration of the scientific and industrial sectors, an effort Barótfi highlighted as notably absent in areas burdened by significant social challenges, such as neurodegenerative diseases.

In the terminal phases of research, MSD is assessing antibody-drug conjugates (ADC) that have shown promise against lung and breast cancers.

Barótfi described ADCs as having the potential to revolutionize treatment modalities in oncology, akin to immunotherapy, by binding chemotherapy agents to antibodies that target tumor cells specifically, thereby reducing side effects typical of conventional chemotherapy.

Nanotechnology is also being explored to enhance drug efficacy and minimize side effects.

Researchers are developing nanosensors capable of providing continuous data from circulating blood parameters, including identifying circulating tumor DNA for early disease detection.

Barótfi anticipates significant advancements in early cancer detection methods within the next five to ten years, attributing broader implications for infectious disease therapies and diagnostic applications.

He also mentioned the significance of drug-device combinations in fields like cardiology, citing examples such as drug-coated stents for coronary artery clearing and insulin pumps for diabetes management.

As noted by Barótfi, the coming decade may witness substantial breakthroughs in pharmaceutical innovation, enhancing recovery rates and overall patient outlooks.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
IMF Upgrades Global Growth Forecast as Weaker Dollar Supports Outlook
House Republicans Move to Defund OECD Over Global Tax Dispute
France Opens Criminal Investigation into X Over Algorithm Manipulation Allegations
Trump Steamrolls EU in Landmark Trade Win: US–EU Trade Deal Imposes 15% Tariff on European Imports
ChatGPT CEO Sam Altman says people share personal info with ChatGPT but don’t know chats can be used as court evidence in legal cases.
Intel Reports Revenue Beats but Sees 81% Rise in Losses
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
President Trump Diagnosed with Chronic Venous Insufficiency After Leg Swelling
CEO Resigns Amid Controversy Over Relationship with HR Executive
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
Tulsi Gabbard Unveils Evidence Alleging Political Manipulation of Intelligence During Trump Administration
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Trump Announces Coca-Cola to Shift to Cane Sugar in U.S. Production
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Air India Pilot’s Mental Health Records Under Scrutiny
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
Moonshot AI Unveils Kimi K2: A New Open-Source AI Model
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Proposes Supplying Arms to Ukraine Through NATO Allies
US Opens First Rare Earth Mine in Over 70 Years in Wyoming
Bitcoin Reaches New Milestone of $116,000
Severe Heatwave Claims 2,300 Lives Across Europe
Declining Beer Consumption Signals Cultural Shift in Germany
Emails Leaked: How Passenger Luggage Became a Side Income for Airport Workers
Polish MEP: “Dear Leftists - China is laughing at you, Russia is laughing, India is laughing”
Western Europe Records Hottest June on Record
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
China’s Central Bank Consults European Peers on Low-Rate Strategies
France Requests Airlines to Cut Flights at Paris Airports Amid Planned Air Traffic Controller Strike
Poland Implements Border Checks Amid Growing Migration Tensions
Emirates Airline Expands Market Share with New $20 Million Campaign
Amazon Reaches Milestone with Deployment of One Millionth Robot
Yulia Putintseva Calls for Spectator Ejection at Wimbledon Over Safety Concerns
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
×